AstraZeneca extends virtual neuroscience reach
This article was originally published in Scrip
Executive Summary
When AstraZeneca announced in February that neuroscience R&D would be a major target of a restructuring initiative there were concerns that it might exit the whole area (www.scripintelligence.com , 2 February, 2012). To counter those fears, the company line was that it was deeply committed to neuroscience research but would take a more virtual approach that involves tapping into external expertise. As part of that strategy AstraZeneca signed its second and third deals on 12 July.
You may also be interested in...
AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Abalos Raises €12M Series A To Develop Arenavirus-Based Cancer Therapies
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Despite BMS Bid, Celgene Pays $75m Upfront For Immatics Assets Options
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.